AOD-9604
A modified C-terminal fragment of human growth hormone (hGH176-191) that retains fat-burning properties without the anabolic or IGF-1-stimulating effects of full HGH. The most targeted peptide for lipolysis with one of the best safety profiles in peptide research - backed by Phase 3 clinical trial data.
Reviewed & fact-checked by
Dr. Jane Smith, MD, PhDChief Medical Reviewer · Last updated: March 1, 2026
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Is AOD-9604?
AOD-9604 is a stabilised peptide analogue of the C-terminal fragment of human growth hormone (amino acids 176-191). Originally developed by Metabolic Pharmaceuticals in Australia as a pharmaceutical treatment for obesity.
The key insight: the fat-burning effects of HGH are concentrated in the C-terminal fragment, while the anabolic, IGF-1-stimulating, and glucose-dysregulating effects are mediated by other regions. AOD-9604 isolates the fat-burning effect without the side effects.
Mechanism of Action
- Beta-3 adrenergic receptor stimulation -- activates beta-3 adrenoceptors in adipose tissue, triggering lipolysis (breakdown of stored triglycerides)
- Inhibition of lipogenesis -- suppresses conversion of dietary carbohydrates to stored fat
- No IGF-1 stimulation -- unlike full HGH, does not raise IGF-1, avoiding insulin resistance risk
AOD-9604 vs Full HGH
| | AOD-9604 | Full HGH | |---|---|---| | Fat burning | Yes -- targeted | Yes -- systemic | | IGF-1 elevation | No | Yes | | Muscle building | No | Yes | | Safety (clinical data) | Phase 3 complete | Significant side effects | | Cost | Affordable | Very expensive |
Clinical Background
AOD-9604 completed Phase 2b and Phase 3 clinical trials in Australia. No significant cardiovascular, glucose, or IGF-1-related adverse events were recorded -- making it one of the best-characterised research peptides available.
Stacking Interactions
How AOD-9604 interacts with other compounds
AOD-9604 promotes fat mobilisation through lipolysis; Berberine improves insulin sensitivity and fat oxidation through AMPK. Together: fat release + fat burning.
Both peptides are often used in recovery protocols. No significant interaction - safe to co-administer.
Safety Profile — Tier B
Generally safe — moderate evidence
Contraindications
- ●Pregnancy - insufficient data
- ●Active cancer
Side Effects
- ●Mild local reaction at injection site
- ●Mild headache in some users
- ●Transient hypoglycaemia with high doses